VENCLYXTO (venetoclax) was granted a positive opinion from the European Committee for Medicinal Products for Human Use for the treatment of chronic lymphocytic leukemia in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of CLL in...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
